# ANX-188 Thorough QT/QTc Study in Healthy Volunteers

> **NCT01790087** · PHASE1 · COMPLETED · sponsor: **Mast Therapeutics, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ANX-188 Therapeutic Dose
- **DRUG:** ANX-188 Supratherapeutic dose
- **DRUG:** Saline
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT01790087
- **Lead sponsor:** Mast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-04
- **Final completion:** 2013-06
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2015-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01790087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01790087, "ANX-188 Thorough QT/QTc Study in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01790087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*